Table 3
Sites of spread for 192 patients with ocular adnexal lymphoma, classified by histological type. (Column percentages in parentheses)
| Site of spread | Histological category of lymphoma | |||||
|---|---|---|---|---|---|---|
| MZL (82 cases) | LPL (44 cases) | FCL (20 cases) | DLCL (19 cases) | H5 (21 rare variants) | All (192 cases) | |
| Local extraorbital extension | 2 (2%) | 3 (7%) | 5 (25%) | 11 (58%) | 3 (14%) | 24 (13%) |
| Temporalis fossa | 0 | 2 (5%) | 4 (15%) | 7 (37%) | 3 (14%) | 16 (8%) |
| Sinuses | 1 (1%) | 2 (5%) | 1 (4%) | 6 (32%) | 1 (5%) | 11 (6%) |
| Nasopharynx | 1 (1%) | 1 (2%) | 1 (4%) | 1 (5%) | 3 (14%) | 7 (4%) |
| Intracranial | 1 (1%) | 1 (2%) | 0 | 2 (11%) | 3 (14%) | 7 (4%) |
| Nodes | 22 (27%) | 19 (43%) | 13 (50%) | 4 (21%) | 10 (48%) | 68 (35%) |
| Bone marrow | 3 (4%) | 7 (16%) | 2 (8%) | 0 | 11 (52%) | 23 (12%) |
| Spleen | 3 (4%) | 7 (16%) | 2 (8%) | 2 (11%) | 2 (10%) | 16 (8%) |
| Liver | 4 (5%) | 0 | 1 (4%) | 1 (5%) | 2 (10%) | 8 (4%) |
| Skin | 12 (15%) | 7 (16%) | 7 (27%) | 4 (21%) | 6 (29%) | 36 (19%) |
| Salivary gland | 5 (6%) | 1 (2%) | 2 (8%) | 0 | 1 (5%) | 9 (5%) |
| Lung | 4 (5%) | 1 (2%) | 1 (4%) | 2 (11%) | 1 (5%) | 9 (5%) |
| Gut | 2 (2%) | 3 (7%) | 0 | 1 (5%) | 1 (5%) | 7 (4%) |
| Breast | 1 (1%) | 0 | 2 (8%) | 0 | 0 | 3 (2%) |
| Body cavity | 1 (1%) | 3 (7%) | 0 | 0 | 1 (5%) | 5 (3%) |
| Kidney | 1 (1%) | 0 | 2 (8%) | 1 (5%) | 0 | 4 (2%) |
| Heart | 1 (1%) | 0 | 0 | 1 (5%) | 0 | 2 (1%) |
| Muscle | 1 (1%) | 0 | 0 | 1 (5%) | 0 | 2 (1%) |
| Bone | 1 (1%) | 0 | 0 | 0 | 1 (1%) | 2 (1%) |
| Total | 33 (40%) | 25 (57%) | 16 (62%) | 13 (68%) | 21 (100%) | 108 (56%) |
-
↵Pericardial, peritoneal and pleural cavities.
-
MZL = marginal zone lymphoma; LPL = diffuse lymphoplasmacytoid/lymphoplasmacytic lymphoma; FCL = follicle centre lymphoma; DLCL = diffuse large B cell lympoma; H5 = rare histological variants.
